BLOG

Oxurion’s CEO Dr. Patrik De Haes discusses three pipeline candidates for diabetic eye disease

Patrik De Haes, MD, CEO of Oxurion, discusses the company’s three disease-modifying drug candidates for the treatment of diabetic eye disease with EyeWire News at the Ophthalmology Innovation Summit in Chicago.